Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BESTOW-EXTENSION long-term tegoprubart safety and efficacy in kidney transplant recipients
2023-503337-21-00Phase 2Authorised
- Sponsor
- Eledon Pharmaceuticals, Inc.
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of tegoprubart in kidney allograft rejection, sponsored by Eledon Pharmaceuticals, Inc. Primary endpoints: Long-term TEAEs and SAEs incidence, AESIs incidence including thromboembolic events, malignancy, NODAT, PTLD, tremors, cytopenias, infections and 1 more. Planned start Feb 2025; status: authorised.
02
Drugs
tegoprubart
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2023-503337-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503337-21-00.